Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

Meet The Attys For Humana In Price-Fixing MDL Set For Trial No Photo Available

Gianna Ferrarin

Attorneys from Lowey Dannenberg PC and Schneider Wallace Cottrell Kim LLP are teaming up to represent insurance giant Humana in the fi... (more story)

Lax Enforcement Spurs Suits Over Insurers' 'Ghost' Networks No Photo Available

Hannah Albarazi

More patients are alleging that what are known as insurers' ghost networks — directories full of unreachable providers — deny them acc... (more story)

Vax Critic Atty Wants To 'Depoliticize' Shots No Photo Available

Yeji Jesse Lee

Attorney Aaron Siri, who specializes in vaccine cases and has close ties to Health and Human Services Secretary Robert F. Kennedy Jr.,... (more story)